Mirum Q3 LIVMARLI sales $18.8M; raises FY2022 guidance to $70M

Mirum Pharmaceuticals, Inc.

2022-Q3 EPS reported -$3.03 revenue$49,156,000

Net product sales LIVMARLI $18.8M in Q3; YTD $47.2M; raised FY2022 guidance to $70M.
Reported Q3 net loss $35.7M ($1.02/share) vs $47.1M loss ($1.55/share) in Q3 2021.
Positive CHMP opinion for LIVMARLI in Alagille syndrome; EU decision expected Q4 2022.
Positive Phase 3 MARCH data in PFIC; completed public offering netting $86.1M.
Cash $285.3M at Sept 30; upcoming data: EMBARK Ph2b H2 2023, OHANA Ph2b H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Mirum Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: revenue $18.8 million, net income net loss of $35.7 million, EPS $1.02 basic and diluted net loss per share.

Period: the quarter ended September 30, 2022
Revenue: $18.8 million
Net income: net loss of $35.7 million
EPS: $1.02 basic and diluted net loss per share
Result: reported results

Exact text from the filing

99.1 Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI ® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million - Conference call to

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-22-001569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.